Oncolytics Biotech Inc.
NASDAQ:ONCYBiotechnology
+$0.03 today
- Market cap
- $50.41M
- Beta
- 1.08
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.32
Volume 0.38M
Average 1.26M
ONCY EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Oncolytics Biotech Inc.NASDAQ: ONCY
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -CA$12.92M, compared with -CA$6.9M a year earlier. Trailing-twelve-month EBITDA was -CA$36.08M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of CA$0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -13.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CA$12.92M-332.0% QoQ
- Last fiscal yearDec 2025
- -CA$39.41M-13.0% YoY
- LTMMar 2026
- -CA$36.08M-19.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -87.2% | +100.0% | +187.2 pp |
| 1 year | -13.0% | +100.0% | +113.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
CAD · from the income statement
- Latest · FY2025
- (39.41M) CAD
- Year-over-year change
- -13.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.41M) | -13.0% |
| FY2024 | 2024-12-31 | (34.88M) | -72.7% |
| FY2023 | 2023-12-31 | (20.19M) | -7.9% |
| FY2022 | 2022-12-31 | (18.71M) | +9.1% |
| FY2021 | 2021-12-31 | (20.58M) | — |
EBITDA vs competitors
How ONCY compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -19.5% is the 5th highest of 9, against a peer median of -20.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$21.1M USD | -18.3% | — | 265.8% | |
| LTM Mar 2026 | -$29.2M USD | -21.6% | — | 21792.5% | |
| LTM Mar 2026 | -$34.56M USD | -66.8% | — | — | |
| LTM Mar 2026 | -CA$36.08M CAD | -19.5% | — | — | |
| LTM Mar 2026 | -$41.59M USD | +38.3% | — | — | |
| LTM Mar 2026 | -$50.64M USD | -7.0% | — | 32.2% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$115.78M USD | -490.7% | — | — |
| LTM Mar 2026 | -$130.98M USD | +37.9% | — | — | |
| LTM Mar 2026 | -$342.25M USD | -325.9% | — | 4567.0% | |
| Peer median (excluding ONCY) | — | -20.0% | — | 2416.4% | |
Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 360.58K | 301.11K | 298.59K | 87K | 70K |
| Gross Profit | (360.58K) | (301.11K) | (298.59K) | (87K) | (70K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.31M | 11.85M | 13.12M | 21.65M | 18.27M |
| Selling, General & Admin | 10.26M | 8.53M | 11.62M | 13.34M | 21.15M |
| Operating Expenses | 20.56M | 20.38M | 24.74M | 34.98M | 39.41M |
| Depreciation & Amortization | 360.58K | 301.11K | 298.59K | 102K | 96.05K |
| EBITDA | (20.58M) | (18.71M) | (20.19M) | (34.88M) | (39.41M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (20.93M) | (20.68M) | (25.04M) | (34.98M) | (39.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 99K | 528K | 1.33M | 1.2M | 529.64K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (15.88K) | 1.67M | 4.55M | 3.4M | 61.75K |
| Income Before Tax | (20.94M) | (19.01M) | (20.49M) | (31.58M) | (39.35M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 39.42K | 64.52K | 71.87K | 130K | 108.4K |
| Net Income | (20.98M) | (19.08M) | (20.56M) | (31.71M) | (39.46M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.49) | (0.44) | (0.41) | (0.41) | (0.41) |
| EPS (Diluted) | (0.49) | (0.44) | (0.41) | (0.41) | (0.41) |
| Weighted Avg Shares | 53.51M | 58.03M | 67.62M | 76.48M | 95.86M |
| Weighted Avg Shares (Diluted) | 53.51M | 58.03M | 67.62M | 76.48M | 95.86M |
Oncolytics Biotech Inc.
NASDAQ:ONCY
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.